Promoting Patricia Fuller to Vice President of IT this early is premature, unless as the professor and others have pointed out the NDA submission is planned around the Safety Trial results later this year or early next year. Biosante has been able to monitor 3656 patients within the existing structure.
Now monitoring several million patients upon commercialization will require a team and improved database capabilities. This would more than justify the promotion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.